EN DE

Hansoh Pharmaceutical Group (3692) Fair Value & Analysis

Healthcare · HK · Market cap HK$199B

HP Hansoh Pharmaceutical Group 3692 · HK
PriceHK$31.68
Fair ValueHK$18.00
Upside-43.2%
Quality64/100
Watch Hansoh Pharmaceutical Group for free, get notified when fair value or trend changes. Watch for free
Healthy Growth
Highly profitable · 37.0% net margin
Low debt · generates free cash flow
1.21% dividend yield
Mixed vs. peers (7/14)
Wide moat 76/100
Evidence: High Range HK$13.50 – HK$28.17 Share as image

Fair value as of: Jul 13, 2026

From 26 valuation models · updated 25 days ago

Fair value updated Jul 13, 2026, revised from HK$15.58 to HK$18.00 (+15.5%) since Jul 9, 2026. Share price −2.7% over the past month.

A solid business, but screening 43% overvalued on our models.

What matters now

  • The price sits above even our optimistic bull case (HK$28.17). The favourable scenario is already priced in.
  • Solid but not exceptional quality (64/100) and above fair value, neither a clear bargain nor a standout compounder.
  • A fairly wide model range (HK$13.50 to HK$28.17) leaves room in how you read the outcome.
Share this valuation: 𝕏 WhatsApp

Price vs Fair Value (5 years)

HK$43.08 HK$9.09 Fair Value HK$18.00 Mar 2021 Aug 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 13, 2026.

How to read this chart

60‑month range HK$9.09 – HK$43.08 · fair‑value band HK$13.50 – HK$28.17 · the HK$31.68 price screens above the HK$18.00 fair value. Dashed = 300-day average. As of Jul 13, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Hansoh Pharmaceutical Group (3692) currently trades at HK$31.68, while our model-based Fair Value estimate is HK$18.00, implying the stock looks roughly 43.2% overvalued today. We read business quality at 64/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).

Over the trailing twelve months, Hansoh Pharmaceutical Group generated revenue of HK$15.0B at a net margin of 37.0%. Revenue grew 32.0% year over year. It earns a return on equity of 17.4%. The balance sheet holds a net cash position of HK$3.3B. Fundamentals as of Jul 13, 2026

Our scenario range runs from HK$13.50 (bear case) to HK$28.17 (bull case); at HK$31.68, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The last reported earnings sit well below what analysts expect (earnings in transition, for example after write-downs or an earnings dip); whether the stock is cheap or expensive hinges on the expected recovery actually arriving. Read the fair value with that caveat. The share trades about 28% below its 52-week high and 21% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -49% fair-value upside, at -43%, 3692 screens cheaper than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Model BearBaseBull Evidence
Highest evidence
Growth DCF HK$14.05 HK$24.76 HK$43.26 80
Residual Income HK$6.07 HK$7.91 HK$21.89 76
Rev-Margin DCF HK$7.82 HK$11.99 HK$17.51 74
All 26 models by family
DCF Models
FCF DCF HK$14.22 HK$26.10 HK$47.35 38
Owner Earnings HK$12.50 HK$22.88 HK$41.44 31
5Y Revenue Exit HK$7.82 HK$11.96 HK$17.37 39
5Y EBITDA Exit HK$10.82 HK$18.25 HK$27.58 41
5Y P/E Exit HK$13.62 HK$24.15 HK$36.38 38
10Y Revenue Exit HK$9.69 HK$14.40 HK$21.32 36
10Y EBITDA Exit HK$11.84 HK$19.07 HK$30.04 37
10Y P/E Exit HK$13.71 HK$23.44 HK$37.55 35
Earnings-Based
Graham-Dodd HK$6.23 HK$30.95 HK$42.69 54
Lynch FV HK$8.35 HK$11.93 HK$15.51 50
PEG = 1.0 HK$8.35 HK$11.93 HK$15.51 46
EPV HK$7.51 HK$8.66 HK$9.68 59
Dividend Discount
Gordon GGM HK$3.05 HK$6.34 HK$10.05 70
DDM Multi-Stage HK$3.05 HK$5.34 HK$6.65 61
Multiples
P/E Multiple HK$13.74 HK$18.33 HK$22.91 63
P/S Multiple HK$4.65 HK$6.20 HK$7.75 58
P/B Multiple HK$11.68 HK$15.58 HK$19.47 55
EV/EBIT HK$12.62 HK$16.64 HK$20.66 53
EV/EBITDA HK$9.90 HK$13.02 HK$16.13 54
EV/Revenue HK$4.90 HK$6.76 HK$8.62 43
Asset-Based
NCAV (Graham) HK$2.92 HK$3.91 HK$5.84 50
Growth DCF
Growth DCF HK$14.05 HK$24.76 HK$43.26 80
Rev-Margin DCF HK$7.82 HK$11.99 HK$17.51 74
Economic Profit
Residual Income HK$6.07 HK$7.91 HK$21.89 76
ROIC Compounder HK$8.28 HK$11.26 HK$15.21 72
Growth Earnings
Growth-Adj P/E HK$12.48 HK$17.83 HK$23.18 68

Widest divergence: DCF Models (HK$19.07) versus Asset-Based (HK$3.91). Highest evidence: Growth DCF (80).

Key figures & financial health

Revenue (TTM) HK$15.0B
Revenue growth (YoY) +32.0%
Net margin 37.0%
Return on equity 17.4%
Free cash flow HK$6.2B FY2025
P/E ratio 30.7
More key figures
Operating margin 29.6%
EPS (TTM) HK$0.5300
Dividend yield 1.2%
EPS growth (YoY) +45.8%
Net cash HK$3.3B FY2025

Figures from reported company fundamentals · as of Jul 13, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 64/100

Of which business quality 74 · Market factors (momentum, volatility) 39

Profitability 65
Margins and returns on capital today
Quality Growth 62
Are margins and returns improving?
Cashflow 86
Earnings quality: real cash, not paper profit
Fin. Strength 86
Balance sheet, leverage, solvency risk
Investment 54
Disciplined investing over empire-building
Low Volatility 71
Calm price path (market factor)
Momentum 26
Price trend over the last 3–12 months (market factor)
52W Momentum 25
Distance to the 52-week high (market factor)
Net Issuance 78
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

About the company

Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, production, and sale of pharmaceutical products in the People's Republic of China.

Full company description

Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, production, and sale of pharmaceutical products in the People's Republic of China. The company provides products for therapeutic areas, including anti-infection, central nervous system, oncology, and metabolic and other diseases, as well as autoimmune diseases. Its principal products include Ameile, Hansoh Xinfu, Pulaile, Xintai, Xinmei, Gainuo, Tanneng, and Pulaitan; Hengmu, Hengsen, Oulanning, Ailanning, and Ameining; XINYUE; and Saint Luolai, Fulaimei, Ruibote, Fulaidi, Punuoan tablets, etc. It has licence agreements with GlaxoSmithKline Intellectual Property (No.4) Limited to develop, manufacture, and commercialize HS-20089 and HS-20093 for the treatment of patients with extensive-stage small-cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy; Biotheus Inc. to develop, produce, and commercialize bispecific antibody-drug conjugate product; and with Merck Sharp & Dohme LLC (MSD) to develop, manufacture, and commercialize HS-10535, an investigational pre-clinical oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist. The company was founded in 1995 and is headquartered in Shanghai, China. Hansoh Pharmaceutical Group Company Limited operates as a subsidiary of Stellar Infinity Company Ltd.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Hansoh Pharmaceutical Group reported revenue of HK$15.0B in FY2025 versus HK$9.9B in FY2021, a compound +10.9%/yr. Reported net income was HK$5.6B in FY2025, compounding +19.6%/yr from FY2021.

Growth Quality 95/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Latest Revenue (FY 2025)
HK$15.0B
Latest YoY
+22.6%
Avg. growth/yr (3Y)
+17.0%
Avg. growth/yr (5Y)
+11.6%
Avg. growth/yr (9Y)
+12.0%
Revenue +10.9%/yr
FY21 HK$9.9B
FY22 HK$9.4B
FY23 HK$10.1B
FY24 HK$12.3B
FY25 HK$15.0B
Net income +19.6%/yr
FY21 HK$2.7B
FY22 HK$2.6B
FY23 HK$3.3B
FY24 HK$4.4B
FY25 HK$5.6B

3692 screens 43% overvalued. Compare with Jiangsu Hengrui Pharmaceuticals Co →

Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
Share or link this analysis
𝕏 Post WhatsApp LinkedIn Reddit
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Hansoh Pharmaceutical Group · Fair Value
HK$18.00 −43%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Hansoh Pharmaceutical Group Fair Value". https://www.fairvalue-calculator.com/stock/3692

Peer Group

Drug Manufacturers - Specialty & Generic · 625 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 64 · Top 25%
Fair Value upside −43% · Below median
Return on equity (TTM) 17% · Top 25%
Return on assets 9% · Top 25%
Net margin (TTM) 37% · Top 25%
Operating margin (TTM) 30% · Top 25%
Revenue growth 32% · Top 25%
Dividend yield (TTM) 1.2% · Below median

Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/E (TTM) 30.7× · Pricier than median
P/B 5.63× · Pricier than 75% of peers
P/S (TTM) 13.25× · Pricier than 75% of peers
P/FCF 4.1× · Pricier than median
EV/EBITDA 34.0× · Pricier than 75% of peers

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 0 · sector 9
FUTURE 100 · sector 21
PAST 69 · sector 23
HEALTH 100 · sector 97
DIVIDEND 24 · sector 35

VALUE 0: the price sits above our fair-value range.

Insider activity: 40/100

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 13, 2026).

Stock Price Fair Value vs Fair Value
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥53.19 ¥25.94 -51%
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,933 ₹989.50 -49%
Divi's Laboratories Limited DIVISLAB ₹7,316 ₹1,943 -73%
Torrent Pharmaceuticals Limited TORNTPHARM ₹4,763 ₹1,329 -72%
PharmaEssentia Corporation 6446 1,285 TWD 221.01 TWD -83%
Cipla Limited CIPLA ₹1,439 ₹1,001 -30%
Zydus Lifesciences Limited ZYDUSLIFE ₹1,151 ₹703.32 -39%
Lupin Limited LUPIN ₹2,443 ₹2,477 +1%
Mankind Pharma Limited MANKIND ₹2,484 ₹983.11 -60%
Dr. Reddy's Laboratories Limited DRREDDY ₹1,211 ₹874.79 -28%

Compare Hansoh Pharmaceutical Group with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Frequently asked questions

Is Hansoh Pharmaceutical Group (3692) overvalued or undervalued?
As of Jul 13, 2026, our model estimates a fair value of HK$18.00 versus a price of HK$31.68, about −43% (overvalued).
What is the fair value of 3692?
Our model-based fair value for Hansoh Pharmaceutical Group is HK$18.00 (as of Jul 13, 2026), built from audited fundamentals. The current price is HK$31.68.
What is the quality score of 3692?
Hansoh Pharmaceutical Group has a Quality Score of 64/100. It combines two groups: business quality (profitability, growth, cash flow, balance-sheet strength) and market factors (price momentum, distance to the 52-week high, volatility). Both subtotals are shown separately in the detail view.
What is the revenue of Hansoh Pharmaceutical Group (3692)?
Hansoh Pharmaceutical Group reported trailing-twelve-month revenue of about HK$15.0B (latest available figure, as of Jul 13, 2026).
What is the net profit margin of 3692?
The net profit margin of Hansoh Pharmaceutical Group is about 37.0%, meaning it keeps roughly 37.0% of revenue as net income. Based on the latest reported figures.
Does Hansoh Pharmaceutical Group pay a dividend?
Hansoh Pharmaceutical Group currently shows a dividend yield of about 1.30% relative to its recent price (as of Jul 13, 2026).

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.

14 days Pro free · no card

Track Hansoh Pharmaceutical Group and try Pro for 14 days

One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.

Zero risk: nothing is ever charged. After 14 days you decide whether to stay.